Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trazodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 12/20 | 0.98 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.98 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | HLA-A | P04439 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 12/20 | 0.98 |
| ▸ | HTR1A | P08908 | 11/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.98 |
| ▸ | HRH1 | P35367 | 3/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.98 |
| ▸ | DRD1 | P21728 | 2/20 | 0.98 |
| ▸ | DRD4 | P21917 | 2/20 | 0.98 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trazodone SCHEMBL29575935 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10HLA-A | |
| Trazodone SCHEMBL61754 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10HLA-A | |
| Trazodone SCHEMBL29390760 | 0.99 | HTR1A (1.00) | KDM4EALDH1A1HPGDHSD17B10HLA-A | |
| Trazodone SCHEMBL28167 | 0.99 | HTR1A (1.00) | KDM4EALDH1A1HPGDHSD17B10HLA-A | |
| Trazodone SCHEMBL28226073 | 0.98 | HTR1A (0.98) | KDM4EALDH1A1HPGDHSD17B10HLA-A | |
| Trazodone SCHEMBL120883 | 0.97 | HTR1A (0.96) | KDM4EALDH1A1HPGDHSD17B10HLA-A | |
| SCHEMBL11089944 | 0.97 | HTR1A (0.98) | KDM4EALDH1A1HPGDHSD17B10HLA-A | |
| Trazodone SCHEMBL27570399 | 0.94 | DRD2 (0.90) | KDM4EALDH1A1HPGDHSD17B10HLA-A | |
| Trazodone SCHEMBL8741340 | 0.93 | DRD2 (0.89) | KDM4EALDH1A1HPGDHSD17B10HLA-A | |
| Trazodone SCHEMBL23145121 | 0.92 | HTR1A (0.87) | KDM4EALDH1A1HPGDHSD17B10HLA-A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931346-B1 | TRAZODONE COMPOSITION FOR ONCE A DAY ADMINISTRATION | ANGELINI LABOPHARM LLC (US) | 2012-07-18 | — | — | EP | claimed |
| EP-2254564-A1 | COMBINATIONS COMPRISING 3-PHENYLSULFONYL-8-PIPERAZINYL-1YL-QUINOLINE | Glaxo Group Limited (GB) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009074607-A1 | COMBINATIONS COMPRISING 3-PHENYLSULFONYL-8-PIPERAZINYL-1YL-QUINOLINE | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| US-6060642-A | TRANSGENIC MICE MODELS FOR GENE FUNCTION, WHEREIN THE TRANSGENIC MICE ARE CHARACTERIZED BY HAVING ALTERED SEROTONIN 5-HT6 RECEPTOR GENE FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-09 | — | — | US | disclosed |